SYDNEY — CSL shares tumbled to an eight-year low after the Australian biotech reported an 81% slide in first-half profit and confirmed chief executive Paul McKenzie’s surprise exit, leaving former finance chief Gordon Naylor to take the top job on an interim basis, Feb. 11, 2026. Reuters reported the sell-off followed a results package weighed down by restructuring and impairment charges and softer performance across key businesses.
Why CSL shares sank on the day
CSL shares were hit by the combination of collapsing statutory profit and a leadership reset that landed without much runway. The company reported net profit after tax of about US$401 million for the six months ended Dec. 31, down 81% from a year earlier, after roughly US$2 billion in restructuring and impairment charges, according to the Financial Times. Investors also had to digest weaker sales in parts of the core plasma franchise and setbacks tied to the vaccine and iron deficiency businesses.
Management emphasized that “underlying” profit looked very different. Excluding one-offs, profit declined 7% and revenue slipped 4% to about US$8.3 billion, Reuters said. Even so, CSL shares reacted sharply because the reported slump and the scale of the charges underscored the depth of the clean-up now underway.
CEO exit: board hands the wheel to Gordon Naylor
The leadership change landed first, then the numbers. McKenzie stepped down after the market close on Feb. 10, with CSL shares immediately under pressure as investors questioned succession planning and strategic clarity. The board appointed Naylor — a long-time CSL executive and former CFO — as interim CEO while a search begins for a permanent successor, Reuters reported.
In commentary on the shake-up and earnings shock, Reuters Breakingviews said the abrupt CEO retirement and the lack of a named successor amplified investor unease just as the company was asking the market to look past a profit collapse driven by heavy charges.
Heavy charges, write-downs and what they covered
The first-half result was dominated by restructuring and impairment items that management linked to a broader transformation effort and reassessment of parts of the portfolio. The Financial Times reported CSL booked a US$1.1 billion write-down in the value of its vaccine and iron supplement divisions, alongside the broader hit from restructuring and impairments. That mix matters because it suggests the pressure on CSL shares is not just a one-quarter “miss,” but also a sign the company is reworking assumptions about growth, profitability and the path forward in businesses outside the plasma engine.
At the same time, CSL maintained full-year guidance and pointed to a stronger second half driven by immunoglobulin, albumin and newer launches, Reuters said. The market response showed that for now, CSL shares are trading more on confidence in execution than on guidance alone.
What investors are watching next
With Naylor in the interim role, the key near-term questions for CSL shares are whether the company can:
demonstrate momentum in the plasma collection-and-supply chain and defend margins;
stabilize the vaccine business amid softer U.S. vaccination demand;
clarify the future structure of the group after months of debate about a potential break-up; and
show the write-downs are a “reset,” not a prelude to more impairments.
In Australia, the mood around the stock has been tense for months. The Australian Financial Review reported management faced pointed questioning as profit slumped and the board transitioned leadership, with investors looking for evidence the company can regain operational consistency and credibility. AFR coverage highlighted the size of the write-downs and the challenge of meeting guidance after a weak first half.
Continuity over time: how CSL got here
For long-time holders, the shock move in CSL shares is the latest chapter in a multi-year stretch of volatile strategy calls and shifting expectations.
Vifor deal: In late 2021, CSL agreed to buy Switzerland’s Vifor Pharma in an all-cash deal worth about US$11.7 billion as it sought to diversify beyond plasma. Reuters reported the acquisition as a major bet on iron deficiency and nephrology drugs — a move now being re-scrutinized as impairment charges mount.
Seqirus spin-off plan: In August 2025, CSL said it planned to spin off its influenza vaccine unit, CSL Seqirus, and flagged job cuts and a buyback to support a broader reorganization. Reuters reported the plan, which became central to the market debate about whether the company was simplifying the portfolio or risking distraction.
Delay and guidance reset: Two months later, CSL delayed the Seqirus spin-off amid U.S. market volatility and cut its profit outlook, a move that again knocked CSL shares and kept investor focus on vaccine demand and execution risk. Reuters reported the delay and revised expectations, framing the demerger timeline as increasingly dependent on market conditions.
Put together, those steps show how quickly the narrative around CSL shares shifted — from diversification and structural change to impairment-driven resets and a sudden CEO transition.
Bottom line for CSL shares
CSL shares are now in a “show me” phase. The company says the statutory slump was dominated by one-off charges and maintains its outlook, but investors are likely to demand clearer proof that the transformation is working and that the latest write-downs represent a clean break from past assumptions. In the near term, the market will watch for updates on the CEO search, evidence of stabilization in vaccine demand, and whether the plasma business can return to steadier growth — the mix that historically underpinned CSL’s premium valuation.
For now, the steep fall in CSL shares signals the market’s verdict: management credibility and execution certainty matter as much as the headline numbers, especially when an 81% profit slump and a sudden CEO exit hit within days of each other.
